LUDIOMIL
LOE ApproachingNDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUDIOMIL is an oral tablet small-molecule antidepressant approved in 1980 by Novartis. The specific indication and mechanism of action are not documented in available data. It represents a mature psychiatric therapeutic with decades of clinical use.
LOE Approaching
With LOE approaching and minimal current job openings (0 linked roles), the product is in defensive portfolio mode; expect focus on retention and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LUDIOMIL offers limited career growth opportunity; zero current job openings and LOE-stage status indicate a consolidating franchise focused on operational efficiency and legacy patient management. This role is suited for professionals seeking stability in a mature product rather than upward trajectory or innovation exposure.
Brand ManagerMedical Science Liaison
Worked on LUDIOMIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.